Evidence map›Paper›PMID 35310897›Full record

ArticleDer Onkologe : Organ der Deutschen Krebsgesellschaft e.V2022

[Management of infections in patients with cancer].

Annika Yanina Classen, Michael Sandherr, Jörg Janne Vehreschild, Marie von Lilienfeld-Toal

Open access · bronzeAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Der Onkologe : Organ der Deutschen Krebsgesellschaft e.V, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Annika Yanina ClassenMedizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Universität zu Köln, Kerpener Straße 62, 50937 Köln, Deutschland.
Michael SandherrSchwerpunktpraxis für Hämatologie und Onkologie, MVZ Penzberg, Weilheim, Deutschland.
Jörg Janne VehreschildMedizinische Fakultät und Uniklinik Köln, Klinik I für Innere Medizin, Universität zu Köln, Kerpener Straße 62, 50937 Köln, Deutschland.
Marie von Lilienfeld-ToalKlinik für Innere Medizin II, Hämatologie und internistische Onkologie, Universitätsklinikum Jena, Jena, Deutschland.
University Hospital Cologne · DELeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DEPraxis für Hämatologie und Onkologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with cancer are at increased risk of infection due to disease-associated or therapy-induced immunosuppression. Taking into account globally increasing antimicrobial resistance rates and negative effects associated with antibiotic treatments, the effective, appropriate and guideline-conform use of anti-infectives must be promoted in this clinical setting. The application of antibacterial prophylaxis should be limited to high-risk patients. Infection diagnostics and therapeutic strategies differ depending on the extent of expected immunosuppression and the patient's individual risk factors.

Indexed as

Antibiotic prophylaxisAntibiotic stewardshipDrug resistance, microbialImmunosuppressionInfections/risk factors

Identifiers

PMID35310897
PMCPMC8922085
OpenAlexW4220700053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.